TreSMI shakes up the market for rare lung diseases

United Therapeutics (UTHR) is likely to maintain its trend for several reasons. With Tyvaso, the company is positioned as a market leader in the treatment of rare lung diseases such as pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). At the end of March/early April, Phase 3 study data for the treatment of IPF is expected to be released, which, in the event of subsequent approval, could generate an additional revenue of $5.4 billion by Oppenheimer's estimates through 2033. The increasing...